

REMARKS

Claims 1-63 are pending. The Office Action restricts the invention into four groups as follows:

Group I: Claims 1-24,42-44,63 drawn nodulisporic acid compound and to spot on formulation comprising a nodulisporic acid derivative, carrier, and optionally a crystallization inhibitor, classified in class 514, subclass 410, class 548 subclass 417.

Group II: Claims 25-41,45,46,48-52, drawn to method of applying to mammals, fish, birds a composition comprising an nodulisporic acid derivative to treat parasite infestation, classified in class 514, subclass 410.

Group III: Claim 47, drawn to method of obtaining a detectable plasma concentration of parasiticides comprising applying to the mammal a formulation comprising nodulisporic acid derivative, classified in class 514, subclass 410.

Group IV: Claim 53-62, drawn to preparing compounds of formula I, classified in class 548, subclass 417.

In compliance with the Restriction Requirement, Applicants elect to prosecute the invention of Group I, claims 1-24,42-44,63. This election is made with traverse.


Furthermore, it is explicitly stated that these amendments should not give rise to any estoppel, as they are not narrowing amendments.

If any fee or extension of time is required to obtain entry of this Response, the undersigned hereby petitions the Commissioner to grant any necessary time

extension and authorizes charging Deposit Account No. 502354 for any such fee not submitted herewith.

The Examiner is invited to contact the undersigned at 678-638-3805, at the Examiner's convenience, to resolve any issues concerning this Response.

Respectfully submitted,



Judy Jarecki-Black, Ph.D., J.D.
Registration No. 44,170

21 April 2006

Merial Limited
3239 Satellite Blvd.
Duluth, Georgia 30096
678-638-3805
678-638-3350 (fax)